Diabetes Mellitus, Type 2CEADNCT03968380
Contextualizing Evidence for Action on Diabetes - Population Survey
An observational study of Diabetes Mellitus, Type 2, run by Universidad Miguel Hernandez de Elche at 1 site in Ecuador.
Trial summary
This protocol reflects the first part of a larger mixed-methods study aimed at exploring the process by which global recommendations can be translated into context-specific, evidence-informed action for diabetes prevention in low-resource settings. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- Population survey with biological and physical measurements.
- Type of treatment
- Pill or oral medicine
- How many people
- 1,440 participants
- Where
- 1 siteEcuador
- Study dates
- 13 Oct 2020to Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Geospatial sampling to achieve a representative sample of people aged 18 or more who are currently living in District 17D06, Quito, or Eloy Alfaro District, Esmeraldas (Ecuador), and are able to provide written informed consent.
Who may be able to join
- Age over 18 years
- Providing written informed consent
- Current residence in the study area, defined as at least 20 days of the previous month sleeping in a residence in study zone and no plan to move in the foreseeable future.
Who cannot join
- Unability to provide informed consent (e.g. significant mental impairment)
- Pregnant women and diabetic patients will be excluded from participation on the oral glucose tolerance test.
Trial locations and contacts
1 site in 1 country.
Ecuador1 site, 1 recruiting
- Recruiting
Mari Carmen Bernal Soriano
Esmeraldas, 080102
Mari Carmen Bernal Soriano, maria.bernals@umh.es
About this study
Official title: Contextualizing Evidence for Action on Diabetes in Low-resource Settings: a Mixed-methods Case Study in Quito and Esmeraldas, Ecuador.
This protocol reflects the first part of a larger mixed-methods study aimed at exploring the process by which global recommendations can be translated into context-specific, evidence-informed action for diabetes prevention in low-resource settings. The CEAD project will be carried out in 2 low-resource settings in Ecuador. Here, in recognition that rigorous epidemiological data on diabetes risk and morbidity is needed to explore applicability of potential actions, the investigators will undertake 2 representative cross-sectional population survey using geospatial sampling. We will collect dat by interview in the homes of the participants using WHO STEPS questionnaires and measure participants' physical and biological parameters.
Read the detailed description
Objective: To provide rigorous epidemiological data on diabetes risk and morbidity in Health District 17D06 in Quito, Ecuador; and Eloy Alfaro District, located in the coastal region of Esmeraldas.
Design: The investigators will undertake two cross-sectional population surveys, with representative samples of the selected health districts, to estimate the prevalence of diabetes, impaired glucose tolerance, and NCD risk factors.
Sample design: Participants will be selected using multi-stage cluster sampling. We will use parishes or 'micro-areas' as primary Enumeration Areas (EA) for which official GIS shape files and population estimates are available. The EAs will be randomly selected with a probability proportional to its population density. In urban areas, after having sampled EAs, buildings or homes will be identified by randomly generated GPS points. The investigators will then sample one person at random in each household.
In rural areas, the investigators will randomly select villages from within the samples EAS, and then undertake the simple random sampling of individuals by using an existing census already developed by voluntary health promotors, and digitised by a local NGO. This census will be updated in the 3 months preceding sample selection to ensure accuracy.
Sample size: The sample size is proposed assuming the prevalence of diabetes is no higher than 10%, to provide an estimate with an absolute precision of +/- 3%, with a 95% confidence level. The investigators assume a design effect of 1.5 (recommended in STEPS guideline for complex designs in absence of locally available alternatives) and will further increased the sample size to allow for up to 20% refusal or loss due to individuals not attending their appointment for physical and biological measurements.
Survey procedures: The questionnaire will be designed according to the WHO STEPS NCD risk factor survey forms , and some survey-specific questions. Detailed demographic information will also be included following the WHO STEPS core questions and extended questions (highest level of education, ethnicity, marital status, employment status and household income). Cultural adaptations to the questions will be made as required.
The questions will be used to compile a purpose designed electronic survey form loaded onto tablets purchased for the research. The survey tool will be pre-piloted before the survey, after training the data collection team.
Thirty trained interviewers will establish survey eligibility, solicit informed consent, and carry out the survey in the participant's home. Composition of the survey team will be gender balanced, and include staff who represent local cultural, ethnic and religious groups. The survey will be carried out in Spanish but some interviewers will also be fluent in Quechua, Chachi and any other relevant indigenous language to translate questions verbally if required. Data collection in rural areas will engage the volunteer health promotors. The surveyors will arrange an appointment for physical and biological measurements together with the participant considering geographical convenience and availability. Individuals with a fasting blood glucose ≥ 126 mg/dl and/or a 2 hour plasma glucose ≥ 200 mg/dl, or blood pressure over 140/90 mmHg will be referred to their local health facility for care. All participants will receive the results of their physical measurements and blood analyses and will receive a health promotion booklet about diabetes, cardiovascular risk, and the importance of healthy diet and physical activity.
Physical measurements and laboratory: Weight, height, waist circumference will be measured and we will include limited biochemical measurements (fasting blood glucose, cholesterol and creatinine) analysed at regional reference laboratories. Participants will also undergo an Oral Glucose Tolerance Test (OGTT). Survey participants will be invited to a well-lit hygienic location after at least 8 hours fasting. Appointments will be first thing in the morning and participants will be instructed to eat or drink nothing but water from 10pm the night before. Instructions for fasting will be given on the appointment card given to the participants the survey day and telephone reminders will be sent when possible. All participants will receive breakfast after the OGTT test. Diabetic patients on medication will be asked to bring their medication and take it immediately after their breakfast after blood draw. They will not be asked to complete an OGTT. Similarly, pregnant women are eligible to participate in the study but will not undergo an OGTT, only fasting blood glucose. In order to ensure absence of pregnancy, the investigators will provide pregnancy tests to women in fertile age who are unable to confirm the absence of pregnancy at the household interview. Steps will be taken to minimise variability (at study zone level) in the pre-analytical treatment of samples. Blood extraction, storage and transportation will follow standard infection control measures.
Data management and analysis: Stickers with Quick Response (QR) codes that can be scanned by the android devices at each step will be used to ensure linkage of data collected in participant's home, their physical and biological measurements and laboratory results. The investigators will use and modify the WHO STEPS forms where possible and import them to Kobo toolbox free open source software (or ODK collect if necessary). Stata/SE (StataCorp, Texas, U.S.A.) Version 12.1. will be used for statistical analysis. The prevalence of impaired glucose tolerance, diabetes, and the other NCD risk factors will be calculated with 95% confidence intervals. Outcomes will be disaggregated by sex, age group, ethnicity and socioeconomic position. Geographical variation in survey outcomes will also be described. Steps will be taken to prevent missing data, but some level is unavoidable and we will incorporate methods analysing missing data or data from uncertain sources when necessary.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- Population survey with biological and physical measurements.
- Keywords
- Implementation science, Noncommunicable disease, Diabetes Mellitus, Type 2, Public Policy, Delivery of Health Care
- Medical subject headings
- Diabetes Mellitus, Type 2, Noncommunicable Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Population survey with biological and physical measurements.Other
Individuals will be interviewed in their homes by trained interviewers. At a later date, in a location agreed with the study team, a sample of blood will be taken and we will measure fasting glucose, cholesterol level and creatinine. We will measure participants' height, weight, waist circumference and blood pressure. An Oral Glucose Tolerance Test (OGTT) will be performed on non-diabetic and/or non-pregnant participants.
| Study group | Role | What they receive |
|---|---|---|
| Population in Quito | 720 randomly chosen people living in District 17D06, Quito (Ecuador) Receives: Other: Population survey with biological and physical measurements. | |
| Population in Esmeraldas | 720 randomly chosen people living in Eloy Alfaro District, Esmeraldas (Ecuador) Receives: Other: Population survey with biological and physical measurements. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glucose Tolerance
New cases of diabetes will be identified by performing the Oral Glucose Tolerance Test. Participants will drink a solution containing 75 g of glucose and their plasma glucose will be measured 2 hours later. Glucose concentration will be given in mg/dl. Individuals will be classified as having impaired glucose tolerance if glycemia after 2 hours is higher than 200 mg/dl and at risk of developing diabetes if he or she has a glicaemia between 140 and 199 mg/dl. Already diagnosed diabetic patients and pregnant women will not undergo this test.
Measured: Blood sampling 2 hours after drinking a glucose solution of known concentration
Secondary outcomes (9)
Fasting blood glucose
We will measure fasting blood glucose using venous blood samples analysed at regional reference laboratories. Results will be given in mg/dl and we will consider an individual to have impaired fasting blood glucose if their value is higher than 126 mg/dl.
Measured: Venous blood sampling will be the first thing in the morning after at lease 8 hours fasting.
Obesity
Obesity will be measured as a body mass index equal or higher to 30, being body mass index defined as weight divided by squared height. Weight will be measured in kg and height in cm.
Weight, height, and waist circumference will be measured in according to the technical specifications recommended in the STEPS guideline, in a separate area to ensure participant privacy.
Measured: At the moment of the survey
Blood pressure
We will measure participants' blood pressure in a separate room ensuring privacy. Measurements will be taken twice within a 2-minute interval to ensure reliability. If values differ more than 5 mmHg, a third measurement will be taken and the final value will be the average of the three measured pressures. Results will be given in mmHg and we will consider an individual to have arterial hypertension if their blood pressure exceeds 90/140 mmHg for diastolic and systolic pressure, respectively.
Measured: At the moment of the survey
Cholesterol
We will measure blood cholesterol using venous blood samples analysed at regional reference laboratories. Results will be given in mg/dl and we will consider an individual to have high blood cholesterol if their value is higher than 200 mg/dl.
Measured: Venous blood sampling will be the first thing in the morning after at least 8 hours fasting.
Tobacco consumption
We will ask participants about their tobacco consumption including frequency and type of products (number of cigarettes, cigars, etc per day or week) as well as past habits, starting age and whether they have tried to quit smoking.
The questionnaire used for this purpose will include sections of the WHO STEPS NCD risk factor survey forms and cultural adaptations will be made as required.
Measured: At time of survey, or ever. Frequency for current smokers measured with reference to usual days and weeks.
Alcohol consumption
We will ask participants about their current and past drinking habits including type of drink and monthly, weekly or daily frequency.
The questionnaire used for this purpose will include sections of the WHO STEPS NCD risk factor survey forms and cultural adaptations will be made as required.
Measured: At time of survey, in reference to the previous week, month and over the 12 months prior to survey.
Fruit and vegetable intake
We will ask participants about their weekly consumption of fruit and vegetables. The questionnaire used for this purpose will include sections of the WHO STEPS NCD risk factor survey forms and cultural adaptations will be made as required.
Measured: At time of survey in reference to usual days and weeks.
Physical activity
We will ask participants about their physical activity patterns. We will include questions addressing moderate or vigorous physical activity as part of their work, traveling habits (walking, bicycle) or whether they practice any sport or physical exercise as a recreational activity.
The questionnaire used for this purpose will include sections of the WHO STEPS NCD risk factor survey forms and cultural adaptations will be made as required.
Measured: At time of survey in reference to usual days and weeks.
Waist circumference
Waist circumference will be measured in cm and we will consider an individual to have high cardiovascular risk if it is higher than 88 cm for women and 102 cm for men.
Weight, height, and waist circumference will be measured in according to the technical specifications recommended in the STEPS guideline, in a separate area to ensure participant privacy.
Measured: At time of survey.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2019
- Study start13 Oct 2020
- Primary completionDec 2022 (estimated)
- Study completionDec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 1,440 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidad Miguel Hernandez de Elche
- Sponsor type
- University, hospital or other
- Collaborators
- European Research Council
- Responsible party
- Principal investigator, Lucy Anne Parker, Universidad Miguel Hernandez de Elche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03968380
- Sponsor's protocol ID
- ERC-2018-STG-804761
- Acronym
- CEAD
- Status last verified
- Jan 2021
- First submitted
- 27 May 2019
- Last updated
- 15 Jan 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Contextualizing Evidence for Action on Diabetes in Low-resource Settings: a Mixed-methods Case Study in Quito and Esmeraldas, Ecuador.
- ClinicalTrials.gov ID
- NCT03968380
- Acronym / sponsor ID
- CEAD / ERC-2018-STG-804761
- Conditions
- Diabetes Mellitus, Type 2
- Keywords
- Implementation science, Noncommunicable disease, Diabetes Mellitus, Type 2, Public Policy, Delivery of Health Care
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,440 participants (estimated)
- Lead sponsor
- Universidad Miguel Hernandez de ElcheUniversity, hospital or other
- Collaborators
- European Research Council
- Study start
- 13 Oct 2020 (actual)
- Primary completion
- Dec 2022 (estimated)
- Study completion
- Dec 2023 (estimated)
- First posted
- 30 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This protocol reflects the first part of a larger mixed-methods study aimed at exploring the process by which global recommendations can be translated into context-specific, evidence-informed action for diabetes prevention in low-resource settings. The CEAD project will be carried out in 2 low-resource settings in Ecuador. Here, in recognition that rigorous epidemiological data on diabetes risk and morbidity is needed to explore applicability of potential actions, the investigators will undertake 2 representative cross-sectional population survey using geospatial sampling. We will collect dat by interview in the homes of the participants using WHO STEPS questionnaires and measure participants' physical and biological parameters.
Detailed description
Objective: To provide rigorous epidemiological data on diabetes risk and morbidity in Health District 17D06 in Quito, Ecuador; and Eloy Alfaro District, located in the coastal region of Esmeraldas.
Design: The investigators will undertake two cross-sectional population surveys, with representative samples of the selected health districts, to estimate the prevalence of diabetes, impaired glucose tolerance, and NCD risk factors.
Sample design: Participants will be selected using multi-stage cluster sampling. We will use parishes or 'micro-areas' as primary Enumeration Areas (EA) for which official GIS shape files and population estimates are available. The EAs will be randomly selected with a probability proportional to its population density. In urban areas, after having sampled EAs, buildings or homes will be identified by randomly generated GPS points. The investigators will then sample one person at random in each household.
In rural areas, the investigators will randomly select villages from within the samples EAS, and then undertake the simple random sampling of individuals by using an existing census already developed by voluntary health promotors, and digitised by a local NGO. This census will be updated in the 3 months preceding sample selection to ensure accuracy.
Sample size: The sample size is proposed assuming the prevalence of diabetes is no higher than 10%, to provide an estimate with an absolute precision of +/- 3%, with a 95% confidence level. The investigators assume a design effect of 1.5 (recommended in STEPS guideline for complex designs in absence of locally available alternatives) and will further increased the sample size to allow for up to 20% refusal or loss due to individuals not attending their appointment for physical and biological measurements.
Survey procedures: The questionnaire will be designed according to the WHO STEPS NCD risk factor survey forms , and some survey-specific questions. Detailed demographic information will also be included following the WHO STEPS core questions and extended questions (highest level of education, ethnicity, marital status, employment status and household income). Cultural adaptations to the questions will be made as required.
The questions will be used to compile a purpose designed electronic survey form loaded onto tablets purchased for the research. The survey tool will be pre-piloted before the survey, after training the data collection team.
Thirty trained interviewers will establish survey eligibility, solicit informed consent, and carry out the survey in the participant's home. Composition of the survey team will be gender balanced, and include staff who represent local cultural, ethnic and religious groups. The survey will be carried out in Spanish but some interviewers will also be fluent in Quechua, Chachi and any other relevant indigenous language to translate questions verbally if required. Data collection in rural areas will engage the volunteer health promotors. The surveyors will arrange an appointment for physical and biological measurements together with the participant considering geographical convenience and availability. Individuals with a fasting blood glucose ≥ 126 mg/dl and/or a 2 hour plasma glucose ≥ 200 mg/dl, or blood pressure over 140/90 mmHg will be referred to their local health facility for care. All participants will receive the results of their physical measurements and blood analyses and will receive a health promotion booklet about diabetes, cardiovascular risk, and the importance of healthy diet and physical activity.
Physical measurements and laboratory: Weight, height, waist circumference will be measured and we will include limited biochemical measurements (fasting blood glucose, cholesterol and creatinine) analysed at regional reference laboratories. Participants will also undergo an Oral Glucose Tolerance Test (OGTT). Survey participants will be invited to a well-lit hygienic location after at least 8 hours fasting. Appointments will be first thing in the morning and participants will be instructed to eat or drink nothing but water from 10pm the night before. Instructions for fasting will be given on the appointment card given to the participants the survey day and telephone reminders will be sent when possible. All participants will receive breakfast after the OGTT test. Diabetic patients on medication will be asked to bring their medication and take it immediately after their breakfast after blood draw. They will not be asked to complete an OGTT. Similarly, pregnant women are eligible to participate in the study but will not undergo an OGTT, only fasting blood glucose. In order to ensure absence of pregnancy, the investigators will provide pregnancy tests to women in fertile age who are unable to confirm the absence of pregnancy at the household interview. Steps will be taken to minimise variability (at study zone level) in the pre-analytical treatment of samples. Blood extraction, storage and transportation will follow standard infection control measures.
Data management and analysis: Stickers with Quick Response (QR) codes that can be scanned by the android devices at each step will be used to ensure linkage of data collected in participant's home, their physical and biological measurements and laboratory results. The investigators will use and modify the WHO STEPS forms where possible and import them to Kobo toolbox free open source software (or ODK collect if necessary). Stata/SE (StataCorp, Texas, U.S.A.) Version 12.1. will be used for statistical analysis. The prevalence of impaired glucose tolerance, diabetes, and the other NCD risk factors will be calculated with 95% confidence intervals. Outcomes will be disaggregated by sex, age group, ethnicity and socioeconomic position. Geographical variation in survey outcomes will also be described. Steps will be taken to prevent missing data, but some level is unavoidable and we will incorporate methods analysing missing data or data from uncertain sources when necessary.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Population in Quito | – | Other: Population survey with biological and physical measurements.720 randomly chosen people living in District 17D06, Quito (Ecuador) |
| Population in Esmeraldas | – | Other: Population survey with biological and physical measurements.720 randomly chosen people living in Eloy Alfaro District, Esmeraldas (Ecuador) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Geospatial sampling to achieve a representative sample of people aged 18 or more who are currently living in District 17D06, Quito, or Eloy Alfaro District, Esmeraldas (Ecuador), and are able to provide written informed consent.
Key inclusion criteria (3 listed)
- Age over 18 years
- Providing written informed consent
- Current residence in the study area, defined as at least 20 days of the previous month sleeping in a residence in study zone and no plan to move in the foreseeable future.
Key exclusion criteria (2 listed)
- Unability to provide informed consent (e.g. significant mental impairment)
- Pregnant women and diabetic patients will be excluded from participation on the oral glucose tolerance test.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Population survey with biological and physical measurements.Individuals will be interviewed in their homes by trained interviewers. At a later date, in a location agreed with the study team, a sample of blood will be taken and we will measure fasting glucose, cholesterol level and creatinine. We will measure participants' height, weight, waist circumference and blood pressure. An Oral Glucose Tolerance Test (OGTT) will be performed on non-diabetic and/or non-pregnant participants. | Other | Population in Esmeraldas, Population in Quito |
Primary outcome
Glucose Tolerance
Time frame: Blood sampling 2 hours after drinking a glucose solution of known concentration
New cases of diabetes will be identified by performing the Oral Glucose Tolerance Test. Participants will drink a solution containing 75 g of glucose and their plasma glucose will be measured 2 hours later. Glucose concentration will be given in mg/dl. Individuals will be classified as having impaired glucose tolerance if glycemia after 2 hours is higher than 200 mg/dl and at risk of developing diabetes if he or she has a glicaemia between 140 and 199 mg/dl. Already diagnosed diabetic patients and pregnant women will not undergo this test.
9 secondary outcomes
Fasting blood glucose
Time frame: Venous blood sampling will be the first thing in the morning after at lease 8 hours fasting.
Obesity
Time frame: At the moment of the survey
Blood pressure
Time frame: At the moment of the survey
Cholesterol
Time frame: Venous blood sampling will be the first thing in the morning after at least 8 hours fasting.
Tobacco consumption
Time frame: At time of survey, or ever. Frequency for current smokers measured with reference to usual days and weeks.
Alcohol consumption
Time frame: At time of survey, in reference to the previous week, month and over the 12 months prior to survey.
Fruit and vegetable intake
Time frame: At time of survey in reference to usual days and weeks.
Physical activity
Time frame: At time of survey in reference to usual days and weeks.
Waist circumference
Time frame: At time of survey.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2021.
Related trials for Diabetes Mellitus, Type 2
Recruiting
Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
Heart Failure, Diabetes
Recruiting
Continuous Glucose Monitoring Systems in People With Type 2 Diabetes Not Treated With Insulin
Type 2 Diabetes
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
Active, not recruitingObservational study
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Not yet recruitingObservational study
Beta-2-Trace Protein in Diabetic Nephropathy
Diabetic Nephropathy Type 2, Type 2 Diabetes Mellitus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes Mellitus, Type 2, run by Universidad Miguel Hernandez de Elche at 1 site in Ecuador.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ecuador. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Lucy Anne Parker (+34 965919516, lparker@umh.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glucose Tolerance (time frame: Blood sampling 2 hours after drinking a glucose solution of known concentration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2021.